Sunday, January 21, 2007

Registration opens from 1:00 pm to 5:00 pm

5:00 – 8:00 pm

Opening Session

Sunshine Peak/Mt. Werner

Orphan Drugs
Lester A. Mitscher, University of Kansas - Program Chair

Lester A. Mitscher, University of Kansas – Orphan Drugs: An Ever Expanding Drug Category

Zhenkun Ma, Global Alliance for TB Drug Development – Development of New Therapies against Tuberculosis

Paul O’Neill, University of Liverpool - Antimalarial Chemotherapy in the 21st Century; Recent Advances in the Development of Drugs Targeting the Hemoglobin Degradation Pathway

8:00 – 10:00 pm

Welcome Reception

Storm Peak
 

Monday, January 22, 2007

7:00 am

Continental Breakfast

Prefunction Area

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

General Oral Session

Bryan Norman, Eli Lilly & Company – Program Chair 

4:00 – 8:00 pm

Evening Session

Sunshine Peak/Mt. Werner

Methods for Fluoro Substituent Introduction into Organic Molecules - Victor Snieckus, Queen’s University – Program Chair

Sandro Mecozzi, University of Wisconsin - A New View of the Role of Fluorine in Medicinal Chemistry

Stephen DiMagno, University of Nebraska - Recent Progress with Nucleophilic Fluorinating Agents

Junji Ichikawa, The University of Tokyo - Construction of Fluorinated Heterocycles by Using the Characteristic Reactivities of Fluoro Alkenes
 

Tuesday, January 23, 2007

7:00 am

Continental Breakfast

Prefunction Area

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

Update on the Discovery of Liver-X-Receptor (LXR) Agonists to Raise HDL – Jeff Zablocki,

CV Therapeutics – Program Chair Session Sponsored by CV Therapeutics

Jason W. Szewczyk, Merck Research Labs - Mixed and alpha-Selective LXR Agonists and their Effects in vivo

Matthew Abelman, CV Therapeutics – A Novel Series of Tetracyclic Acridines as Potent LXR Activators

Raju Mohan, Exelixis – A Lesson from the LXR Alphabet….It’s Not Just About the ABCs

Robert Steffan, Wyeth Research - Design of Potent and Selective LXR Agonists From a Series of Quinoline and Indazole  Core Compounds

4:30 – 7:30 pm

Evening Session

Sunshine Peak/Mt. Werner

Biomedical Imaging and Diagnostics – Tony Barrett, Imperial College – Program Chair

David Parker, University of Durham, England - Analysis, Microscopy and Imaging with Lanthanide Probes

Ching H. Tung, Massachusetts General Hospital, Harvard Medical School - Developing fluorescent probes for biomedical imaging

Kai Licha, Schering AG - Fluorescent dyes under influence: design of cyanine conjugates for optical molecular imaging

Kenneth N. Raymond, University of California, Berkeley – High relaxivity and high stability in Gd MRI agents

Game 5 Hockey Match
Sponsored by TDC Research, Inc.

Wednesday, January 24, 2007

7:00 am

Continental Breakfast

Prefunction Area

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

Recent Advances in Organic Chemistry Organized by Colorado State University Chemistry Department – Robert M. Williams, Colorado State University – Program Chair

Louis S. Hegedus – From Microcycles to Macrocycles: Azapenams to Dioxocyclams

Alan J. Kennan - Methods for and Applications of Helical Peptide Self-Assembly

Tomislav Rovis - Catalytic Asymmetric C-C and C-N Bond-Forming Reactions

Yian Shi - Oxidation of Olefins

John L. Wood - Discovery by Synthesis: New Methods for Deoxygenation

Albert I. Meyers - Chiral Oxazolines- Their Legacy in Asymmetric C-C Bond Forming Reactions

1:00 pm

Mountain Lunch & Group Photo

Bashor Picnic Area

2:30 pm

NASTAR Race

4:00 – 7:00 pm

Poster Session

Storm Peak

Jack Hodges, Berry & Associates – Program Chair

7:00 pm

Keynote Banquet & Address

Sunshine Peak/Mt. Werner

Dr. Laura L. Kiessling, University of Wisconsin – Madison
Keynote Address sponsored by Prous Science

Thursday, January 25, 2007

7:00 am

Continental Breakfast

Prefunction Area

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

Picking the Right Pocket: Advances in non-ATP Kinase Inhibitor Design – Michael Rafferty, Program Chair

E. Premkumar Reddy, Temple University School of Medicine - Non-ATP competitive inhibitors of Serine/Theronine and Tyrosine kinases for Cancer Therapy

Daniel Flynn, Deciphera Pharmaceuticals, LLC - Mimicry of endogenous kinase regulation.  Small molecule modulators of kinase conformational switching pockets

Kevin Koch, Array Biopharma - The Design of MEK Inhibitors for the Treatment of Cancer and Inflammatory Disease

1:00 – 4:00 pm

Afternoon Session

Sunshine Peak/Mt. Werner

Kinase Inhibitors in late-stage preclinical and clinical development – Daniel Flynn, Deciphera Pharmaceuticals, LLC – Program Chair

Darrin Stuart, Novartis Institutes for Biomedical Research – Preclinical Development of RAF265: A Novel and Potent Inhibitor of Mutant B-Raf

Sean Buchanan, SGX Pharmaceuticals, Inc. - Fragment-based discovery of BCR-ABL inhibitors for treatment of chronic myelogenous leukemia

James Henry, Eli Lilly & Company - Design, Synthesis and Discovery of a novel Multi-targeted Anti-angiogenic Kinase Inhibitor (MAK)

4:00 pm meeting closes